Topical tacrolimus for the amelioration of breast cancer-related lymphedema: a randomized, double-blind, placebo-controlled phase II/III trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503644-13-00

Enrollment

Registered

2024-05-16

Start date

2024-09-09

Completion date

Unknown

Last updated

2025-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer-related lymphedema

Brief summary

Change in lymphedema volume

Detailed description

Health-related quality of life, Lymphatic flow and - function, Skin fibrosis, Excessive water in the limb (L-Dex score)

Interventions

DRUGTACROLIMUS

DRUGPLACEBO

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
Health-related quality of life, Lymphatic flow and - function, Skin fibrosis, Excessive water in the limb (L-Dex score)	—

Primary

Measure	Time frame
Change in lymphedema volume	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026